【科济生物CARSGEN是哪个国家的品牌？】

科济生物医药（上海）有限公司，成立于2014年10月，是中国较早专注于嵌合抗原受体修饰的T（CAR-T）细胞免疫治疗的创新型企业，同时也是全球实体瘤CAR-T领域的企业之一。

秉承“科学创造，济世救人”的价值观，科济生物始终以“攻克肿瘤，造福患者”为景愿，建立了管理、研发、生产团队。公司现有员工100多人。

科济生物拥有强大的研发能力，拥有一大批自主知识产权的技术储备。

科济生物于2014年11月完成A轮1000万人民币融资，2016年1月完成B轮3000万美元融资，同年又设立了香港及美国子公司。公司将积极拓展海外市场，加速国际化进程，大力推进与国际研究型医院合作，在国内及海外开展更多肿瘤靶点及适应症的研究。

英文翻译：Keji biomedical (Shanghai) Co., Ltd., founded in October 2014, is an innovative enterprise in China that focuses on the immunotherapy of T (car-t) cells modified by chimeric antigen receptor, and also one of the enterprises in the field of car-t solid tumors in the world. Adhering to the value of "scientific creation, saving the world and people", Keji biology has always set up a management, R & D and production team with the goal of "conquering tumors and benefiting patients". The company has more than 100 employees. Keji biology has a strong R & D capability and a large number of technology reserves with independent intellectual property rights. Keji biology completed round a financing of RMB 10 million in November 2014, and round B financing of USD 30 million in January 2016. In the same year, it established Hong Kong and US subsidiaries. The company will actively expand overseas markets, accelerate the internationalization process, vigorously promote cooperation with international research hospitals, and carry out more research on tumor targets and indications at home and abroad.

本文链接： https://www.waitui.com/brand/0ba9651c3.html 联系电话：021-64501828